CION Ameerpet
Almost every treatment your oncologist offers you today existed only inside a trial ten or fifteen years ago. Ovarian cancer clinical trials are how the next set of answers gets found — and, for some women, how a treatment becomes available years before it reaches routine care. Taking part is a real decision with real trade-offs, and it deserves to be explained properly rather than sold to you.
A clinical trial is a research study that tests something in people under a written protocol — a new drug class, a different combination, a different duration of treatment, a new way of choosing treatment from tumour biology, or a better way of managing side effects. The protocol is fixed in advance, approved by an ethics committee, and every result is recorded whether it is good or disappointing. That structure is the whole point: it is what separates a trial from a doctor simply trying something and hoping.
Two fears come up in almost every conversation about ovarian cancer clinical trials, and both deserve a straight answer. The first is being experimented on. In cancer trials you receive at least the current standard of care — the investigational treatment is normally added to it, or compared with it, never substituted for nothing. The second is being watched less closely. In practice the opposite is true: trial participants are seen more often, scanned on a fixed schedule and monitored more tightly than routine care allows, because the protocol demands it.
What a trial is not is a guarantee. The reason a study exists is that nobody yet knows whether the new approach is better. Some trials change practice worldwide; many show no benefit; a few show harm, which is exactly why they are done. Anyone presenting a trial to you as a cure, or as your last hope, is misrepresenting it. Most women with ovarian cancer in India will be treated with standard, guideline-based care, and that care is good care — our guide to ovarian cancer treatment in Hyderabad sets out what it involves.
In an ovarian cancer trial you do not give up proven treatment to take part. The question being tested is whether something added to it, or sequenced differently, does better.
Fixed scan intervals, protocol blood tests and a research nurse who knows your case. The intensity of follow-up is one of the genuine practical benefits.
A trial only opens where there is honest uncertainty. That uncertainty is the reason for it — and the reason no one can promise you what it will do for you.
The NCCN states in every one of its guidelines, including the ovarian cancer guideline, that the best management of any patient with cancer is in a clinical trial, and it specifically encourages participation. In India, trials are not informal: under the New Drugs and Clinical Trials Rules, 2019, every interventional trial needs approval from a registered ethics committee and authorisation from the national regulator, must be registered prospectively with the Clinical Trials Registry – India (CTRI) before the first participant is enrolled, and the sponsor is legally responsible for free medical management of any trial-related injury and for compensation where injury is established. A study that cannot show you its registration number is not a clinical trial. Source: NCCN Clinical Practice Guidelines in Oncology, Ovarian Cancer; New Drugs and Clinical Trials Rules, 2019, Government of India; Clinical Trials Registry – India (ICMR-NIMS).
Most of the difference is not in the medicine. It is in who decides, how closely you are watched, and how much of your time the study asks for. This is the comparison women most often want before they agree to be screened.
| What is being compared | Standard treatment | Inside a clinical trial |
|---|---|---|
| Who chooses your treatment | Your oncologist and the tumour board, adjusting the plan to you as you go. | The protocol sets the plan in advance. In a randomised trial a computer, not your doctor, allocates which arm you are in. |
| What you actually receive | Guideline-based treatment known to work in your situation. | At least that same standard of care, plus or compared with the approach being tested. |
| How closely you are followed | Reviewed each cycle, scanned when there is a reason to scan. | Fixed visit and scan schedule, protocol blood tests, and a research nurse assigned to you. |
| Flexibility | Doses, timing and hospital visits can be adjusted around your life. | Visit windows, washout periods and dose rules are fixed. Missing visits can end participation. |
| Cost | You or your insurer pay for treatment, scans and admissions. | The investigational treatment and protocol-mandated tests are normally provided at no cost to you. Routine care and travel usually are not. |
| What is known about the outcome | Reasonably predictable from published evidence and experience. | Genuinely unknown — that uncertainty is why the study exists. |
| Leaving | You can change your mind about any treatment at any time. | You can withdraw at any point, for any reason, without your standard care being affected. |
*Neither column is automatically the better one. A trial is worth pursuing when what it is testing is relevant to your specific situation and you can realistically attend the visits — not simply because it is available.
The word trial covers studies that are enormously different from one another. Knowing which kind you are being offered changes what it is reasonable to expect from it.
The first time a new agent is given to people, or the first time an existing one is given in a new combination. Small numbers, often across several cancer types rather than ovarian cancer alone, with the aim of establishing a dose and describing side effects rather than proving the treatment works.
Phase 1 studies are usually offered when standard options have largely been used up. They ask a lot: frequent visits, extra blood tests, sometimes overnight stays. Some women get real benefit, and it would be dishonest to present that as the expected outcome rather than the exception.
A larger group, all with the same cancer, given the dose that phase 1 established. The question is whether tumours shrink, whether disease control lasts, and whether the side-effect profile is liveable with. Many phase 2 studies in ovarian cancer now select participants by biology — BRCA status, HRD status or a specific molecular finding — rather than by stage alone.
Most treatments that look promising in phase 2 do not survive phase 3. That is not a failure of the process; it is the process working. A phase 2 result is a reason to test something properly, not a reason to change practice.
The study that changes guidelines. Hundreds or thousands of women are randomly allocated to the current standard treatment or to the standard plus the new approach, and followed for years. Almost every treatment your oncologist offers today, including platinum-based chemotherapy schedules and maintenance strategies, is standard because a phase 3 trial showed it to be.
These are the trials most relevant to a woman who is newly diagnosed or facing a first recurrence, because both arms are credible treatment. If the new approach turns out not to help, participants in the control arm have lost nothing clinically.
After a treatment is approved, phase 4 studies follow large numbers of people to pick up uncommon side effects and to see how the treatment behaves outside the tidy conditions of a trial. Registry and observational studies simply record what happens with routine care, sometimes with an extra blood or tissue sample.
These ask very little of a participant — often nothing beyond consent to have your data or a sample used. If you want to contribute to research without changing your treatment, this is usually the route.
In a randomised trial the allocation is made by chance rather than by your doctor. That feels wrong to most people at first. The reason is that doctors, meaning well, tend to put fitter patients into the treatment they believe in, which makes the result impossible to interpret. Randomisation is the only way to get a clean answer.
Randomisation happens only when there is genuine uncertainty about which arm is better. If it were already known, the trial would not be permitted to open.
This is the fear that stops most women before they start, and it is largely misplaced. In cancer, a placebo is not used instead of treatment when an effective treatment exists. Where a placebo appears, it is added to standard care so that the comparison is standard care plus the new agent against standard care plus a dummy — both arms receive real treatment.
Placebos are used mainly in maintenance studies, where the question is whether continuing something after chemotherapy delays the cancer returning. Blinding matters there because side effects and quality of life are being measured, and knowing which arm you are in changes how symptoms are reported. The consent form must state plainly whether a placebo is involved, and you are entitled to ask before agreeing to anything.
Every protocol has inclusion and exclusion criteria: stage, subtype, how much treatment you have had before, how long since your last dose, kidney, liver, heart and bone-marrow function, other cancers, and how well you are managing daily activity. These are not judgements about you. They exist so the result means something and so that people who would be harmed are kept out.
If you pass screening, consent is a conversation and a document, not a signature at the end of an appointment. You should be given the form to take home, told what the study is testing, what the alternatives are, what extra visits and tests are involved, who pays for what, and who to contact if something goes wrong. Take it home. Discuss it with your family. A trial that will not let you do that is not one to join.
Desperation attracts people who sell hope. Genuine research looks and behaves in specific ways, and these are the signs that what is being offered is something else.
In a legitimate trial the investigational treatment and protocol-mandated tests are provided by the sponsor. Being asked to buy the experimental treatment is the clearest warning sign of all.
Interventional trials in India must be registered with the CTRI before enrolment begins. Ask for the number. A study that cannot give you one should not be recruiting you.
Every trial has a registered ethics committee that approved it and an identified principal investigator. Both should be named in the documents you are given, not described vaguely.
A trial exists because the answer is unknown. Any promise of a cure, or of guaranteed response, is a sales pitch rather than a research protocol.
Screening windows are real, but genuine studies expect you to take the consent form home and discuss it. Pressure to sign immediately is not how ethical recruitment works.
You are entitled to a written participant information sheet in a language you understand, and to a copy of what you sign. Anything less is not valid consent.
If something feels wrong, stop and ask your treating oncologist to look at the paperwork before you sign it. A second opinion costs you a consultation; the alternative can cost far more. You can also book a free consultation and bring the documents with you.
Bring your pathology report, your last CT report, your CA-125 values and your BRCA or HRD result if you have one. In 45 minutes a medical oncologist can tell you where you stand on eligibility, what standard treatment would offer you, and whether looking for a trial is worth the effort in your situation.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. If no trial fits you, we will say so plainly and spend the time on the treatment that does.
There is no single place where every study is listed and no service that matches you automatically. This is the sequence that works, and it starts with a question most women never ask out loud.
The single most useful step, and the one most often skipped. Ask plainly: is there a trial I would be eligible for, here or anywhere in India? Your oncologist knows your stage, your prior treatment and your organ function, which is most of what eligibility turns on. If the answer is no, ask why not — the reason usually tells you whether it might change later.
The Clinical Trials Registry – India lists studies registered to run in India and is the definitive national source; ClinicalTrials.gov lists international studies including many with Indian sites. Search by condition rather than by drug name, and filter for studies that are actively recruiting. Print anything that looks relevant and take it to your appointment rather than acting on it alone.
Most disappointment comes from skipping this step. Look at the stage required, how many previous lines of treatment are allowed, the washout period since your last dose, and whether measurable disease on a scan is needed. A rising CA-125 without measurable disease disqualifies more women than any other single criterion.
Trials increasingly select on tumour biology. Germline and somatic BRCA testing and an HRD score are the results most often required, and they take weeks to come back. Having them already done can be the difference between making a screening window and missing it — and they guide standard maintenance decisions regardless.
Screening involves a scan, blood tests, a review of your original pathology and sometimes a fresh tumour sample. Being screened does not commit you to anything, and a meaningful proportion of women are found not to be eligible at this stage. Ask before you start what the screening itself will require of you and who pays for it.
Read it with someone else. Write your questions down. Ask what happens if you stop, what the treatment costs if the trial ends, how far you will travel and how often, and what standard treatment would offer you instead. If the cancer has returned, our guide to treating recurrent ovarian cancer sets out the standard options a trial would be compared against.
*Trial availability in ovarian cancer is limited everywhere, and far more limited in India than the volume of interest in new ovarian cancer treatments suggests. Not finding a study you fit is the usual outcome, not a failure of your search.
Women usually arrive at this question from one of two directions. Either standard treatment has stopped working and a trial feels like the remaining door, or they have read about new ovarian cancer treatments and want to know whether they are missing something. Both need the same first step: an honest assessment of where you actually stand on eligibility, which takes longer than a ten-minute review slot allows.
Your first consultation at CION is free and runs to about 45 minutes. Bring your pathology report, your most recent CT report, your CA-125 values and your BRCA or HRD result if it has been done. What we can tell you is specific: whether measurable disease is present, how many lines of treatment you have had, whether your kidney, liver and marrow function would pass a typical protocol, and what standard treatment still has to offer you. Every case is discussed at a tumour board rather than decided by one doctor alone.
We should be clear about what we do and do not do here. Chemotherapy, maintenance therapy, genetic counselling, BRCA and HRD testing, nutrition support, survivorship care and follow-up are delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh. Cytoreductive surgery is coordinated with specialist gynaecologic-oncology partner centres, where it is performed and may be billed. Where a trial is a genuine option, enrolment happens at whichever centre holds that study, and our role is to identify it, get your biology results ready in time, and coordinate the referral — not to promise you a place in something we do not run.
The candid part: for most women, at most points in the illness, there will be no trial that fits, and the right answer is well-delivered standard treatment close to home. We would rather tell you that at the first visit than let you spend three months chasing studies you are not eligible for. If that is where you are, start with our complete guide to ovarian cancer and bring your questions to a consultation.
Free and unhurried. Long enough to go through eligibility properly and to say plainly whether looking for a trial is worth your time right now.
Medical oncology, imaging and pathology review the case together, including whether a research route is worth pursuing and what standard care would offer instead.
BRCA and HRD testing and genetic counselling in-house, so a screening window is not lost waiting weeks for a report that should already exist.
Chemotherapy, maintenance and follow-up across 35+ centres in Telangana and Andhra Pradesh, whether or not a trial turns out to be part of your plan.
*CION does not run its own drug trials, and no one at CION will ever ask you to pay for an investigational treatment. Where a study is relevant, we tell you where it is running and help you get there. Decisions for healing, not billing.
A clinical trial is a research study that tests a treatment, a test or a way of delivering care under a written protocol approved by an ethics committee. In ovarian cancer, trials usually test a new drug class or combination added to platinum-based chemotherapy, a different maintenance strategy, or a way of choosing treatment from tumour biology. The guinea-pig fear is understandable but misplaced. Cancer trials do not withhold effective treatment: you receive at least the current standard of care, with the investigational approach added to it or compared against it. In practice participants are monitored more closely than routine care allows, with fixed scan intervals, protocol blood tests and a research nurse assigned to their case. What a trial cannot offer is certainty, because the reason it exists is that nobody yet knows which approach is better.
No. In cancer research a placebo is not substituted for an effective treatment. Where a placebo is used, it is added to standard care, so the comparison is standard treatment plus the new agent against standard treatment plus a dummy. Both arms receive real, active cancer treatment. Placebos appear most often in maintenance studies, where the question is whether continuing something after chemotherapy finishes delays the cancer returning. Blinding matters there because side effects and quality of life are being measured, and knowing your allocation changes how symptoms get reported. Any consent form must state plainly whether a placebo is part of the design, and you are entitled to ask that question before agreeing to be screened. If the answer is vague, that is a reason to pause rather than proceed.
Start by asking your oncologist directly whether there is a study you would be eligible for, anywhere in the country. They know your stage, your prior treatment and your organ function, which is most of what eligibility depends on. Then search the registries yourself. The Clinical Trials Registry – India is the national register and lists studies approved to run here; ClinicalTrials.gov lists international studies including those with Indian sites. Search by condition rather than by drug, and filter for studies that are actively recruiting. Read the eligibility criteria before you get attached to a study, particularly the number of previous treatment lines allowed and whether measurable disease on a scan is required. Print what looks relevant and take it to your appointment rather than acting on it alone.
In a properly conducted trial the investigational treatment and the tests the protocol requires are provided by the sponsor at no cost to you. Routine care that you would have needed anyway, and your travel and accommodation, are usually not covered, so ask for that split in writing before you agree. Being asked to buy the experimental treatment is not how trials work and is the clearest sign that something is wrong. On injury, Indian regulation is explicit: under the New Drugs and Clinical Trials Rules, 2019, the sponsor is responsible for free medical management of any trial-related injury for as long as it is needed, and for financial compensation where the injury is established as related to the trial. The consent documents must set out how to report a problem and who to contact.
You can withdraw at any point, for any reason, without giving an explanation and without your standard treatment being affected. That right is written into every consent form and it is not negotiable. Nobody is entitled to make you feel that leaving lets the team down. Ineligibility is far more common than most people expect. Protocols set limits on stage and subtype, how many previous lines of treatment you have had, how long since your last dose, kidney, liver, heart and bone-marrow function, other active cancers, and how well you manage daily activity. The criterion that disqualifies most women who feel well is the requirement for measurable disease on a scan: a rising CA-125 alone usually does not qualify. None of this is a judgement about you.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house: chemotherapy and maintenance therapy across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling, BRCA and HRD testing, nutrition support, survivorship care and follow-up. Cytoreductive surgery is coordinated with specialist gynaecologic-oncology partner centres, where it is performed and may be billed — we state that upfront rather than leave it to be discovered later. On research, we are equally plain: CION does not run its own drug trials. Where a study is genuinely relevant to your situation, we assess your eligibility, get your BRCA and HRD results ready in time, and coordinate the referral to the centre running it. Every case is discussed at a tumour board.